|
Mar 14
|
1 Small-Cap Stock on Our Buy List and 2 to Avoid
|
|
Mar 11
|
Top Growth Companies With Significant Insider Ownership
|
|
Mar 10
|
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
|
|
Feb 23
|
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025
|
|
Feb 18
|
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
|
|
Feb 18
|
Incyte Stock Sees Relative Strength Rating Rise To 71
|
|
Jan 18
|
Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years?
|
|
Dec 31
|
Corcept Submits Application for Another Cushing's Syndrome Drug
|
|
Dec 30
|
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
|
|
Oct 1
|
Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet
|
|
Oct 1
|
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
|
|
Sep 30
|
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
|
|
Sep 25
|
Does Corcept Therapeutics (CORT) Have a Long Runway for Growth?
|
|
Sep 19
|
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
|
|
Aug 28
|
Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound?
|
|
Aug 27
|
Corcept (CORT) Upgraded to Buy: Here's Why
|
|
Aug 9
|
3 US Growth Companies With High Insider Ownership
|
|
Jul 22
|
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
|
|
Jun 26
|
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
|
|
Jun 24
|
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
|